MaiorcaR., CancariniG.C., BrunoriG., CameriniC., ManiliL.Morbidity and mortality of CAPD and hemodialysis.Kidney Int1993; 43(Suppl 40): S4–15.
2.
BloembergenW.E., PortF.K., MaugerE.A., WolfeR.A.A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis.J Am Soc Nephrol1995; 6: 177–83.
3.
BloembergenW.E., PortF.K., MaugerE.A., WolfeR.A.A comparison of cause of death between patients treated with hemodialysis and peritoneal dialysis.J Am Soc Nephrol1995; 6: 184–91.
4.
HolleyJ.L., BernardiniJ., PerlmutterJ.A., PirainoB.A comparison of infection rates among older and younger patients on continuous peritoneal dialysis.Perit Dial Int1994; 14: 66–9.
5.
KeaneW.F., AlexanderS.R., BailieG.R., BoeschotenE., GokalR., GolperT.A.The Ad Hoc Advisory Committee on Peritonitis Management. Peritoneal dialysis-related peritonitis treatment recommendations: 1996 update.Perit Dial Int1996; 16: 557–73.
6.
JanknegtR., PaulissenA., HooymansP.M., LohmanJJHM, HermensWAJJ. Stability of amphotericin B in CAPD fluid.Perit Dial Int1990; 10: 287–9.
7.
KlineS., LarsenT.A., FieberL., FishbachR., GreenwoodM., HarrisR.Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex.Clin Infect Dis1995; 21: 1154–8.
8.
BalakrishnanA.R., EaswaranK.R.K.Lipid-amphotericin B complex structure in solution: A possible first step in the aggregation process in cell membranes.Biochemistry1993; 32: 4139–44.
